Atlas Antibodies: an Extraordinary Story

Atlas Antibodies is a dynamic Swedish Life Science company dedicated to contributing to increase health and well-being globally by advancing protein science & medical discovery.

Atlas Antibodies was founded in 2006 by researchers from the prestigious Human Protein Atlas project (a Wallenberg funded project), with the aim to make the unique antibodies used in the project available to fellow researchers worldwide.

Based on the idea to create a complete map of human protein expression and localization, the Human Protein Atlas project developed its own set of highly specific antibodies.

These unique antibodies were made commercially available in 2006 by Atlas Antibodies as Triple A (Atlas Antibodies Advanced) Polyclonals. Since then, Atlas Antibodies has also introduced PrecisA Monoclonals (the swedish word "precisa" stands for precise, accurate and targeted) and PrEST Antigens (recombinant human Protein Epitope Signature Tags). All of these products are based on the same high-quality manufacturing principles.

In 2024 Atlas Antibodies has released MolBoolean, a new technology for protein-protein interaction studies.

Our products are used in research for the purpose of understanding and improving human health. Atlas Antibodies is fully owned by Patricia Industries (an Investor company) and follow the high standards of the Investor group and have a high focus on sustainability in all things we do.

Our Core Elements

Human Protein Atlas Integration:

The foundation of our work lies in the extensive data and insights gathered through the Human Protein Atlas project, providing a robust scientific basis for our product development.

By leveraging this comprehensive resource, we can access valuable information to advance your understanding of human proteins and their roles in health and disease.

Comprehensive Coverage:

Atlas Antibodies manufactures over 22,000 primary antibodies meticulously designed and validated to target a wide spectrum of human proteins relevant to diverse research applications.

Our products include: PrecisA Monoclonals, TripleA polyclonals, PrEST Antigens and the newly developed MolBoolean technology for protein-protein interaction studies.

Enhanced Validation:

Enhanced validation ensures the reliability and accuracy of our antibodies by minimizing the risk of nonspecific binding or false positives, thus enhancing the trustworthiness of your experimental outcomes.

Through meticulous testing in diverse experimental conditions, including various tissue types and applications, we ensure consistent performance, and lot-to-lot reproducibility empowering you with the confidence you need in your research findings.

Vision

Our vision is for every therapeutic discovery to be enhanced by our solutions.

Mission

Through our expertise and unique heritage, we provide innovative and high-quality solutions to researchers around the world. By doing so we enable ground-breaking medical discovery, better diagnosis, and patient outcomes.

Sustainability is at the very core of our business

Together with our key stakeholders, we have defined five focus areas within sustainability.

Read more